PDX model details
| PDX ID |
472M Cx |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Castrate |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
10 (5*) |
| Average PDX Generation Time (days +/- SEM) |
51 ± 3 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
472M Cx |
| AR |
N |
| PSA |
N |
| PSMA |
N |
| NE |
Y |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 472M Cx |
CHD7 |
0.53139 |
2.89064 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 472M Cx |
PTEN |
-2.22538 |
0.427685 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 472M Cx |
CDH1 |
-1.29048 |
0.81763 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 472M Cx |
ZFHX3 |
-1.29048 |
0.81763 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 472M Cx |
FANCA |
-1.29048 |
0.81763 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 472M Cx |
TP53 |
-1.20961 |
0.864771 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 472M Cx |
BRCA1 |
-1.26655 |
0.831305 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 472M Cx |
NCOR1 |
-1.29767 |
0.813565 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 472M Cx |
RB1 |
-25.4079 |
0.0000000449 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
472M |
| Sample Site |
Left ilium |
| Sample source |
Biopsy |
| Pathology Tumour Diagnosis |
None |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel |
| |
|
Patient Information
| Patient Number |
472 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
630 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
No information in Gene expression
No information in Drug dosing Table